The University of Southampton
University of Southampton Institutional Repository

Use of statins and risk of fractures

van Staa, Tjeerd-Pieter, Wegman, Sebastiaan, de Vries, Frank, Leufkens, Bert and Cooper, Cyrus (2001) Use of statins and risk of fractures JAMA: The Journal of the American Medical Association, 285, (14), pp. 1850-1855. (doi:10.1001/jama.285.14.1850).

Record type: Article

Abstract

Context: Previous studies have reported lower fracture risks in patients taking 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins).
Objective: To investigate risk of fracture among statin users.
Design: Case-control study of data from the General Practice Research Database (GPRD).
Setting: A total of 683 general clinical practices in the United Kingdom.
Patients: Cases were 81 880 patients aged 50 years or older who had a fracture of the vertebrae, clavicle, humerus, radius/ulna, carpus, hip, ankle, or foot occurring between the enrollment date of their practice into the GPRD and July 1999, paired with 81 880 age-, sex-, and practice-matched controls.
Main Outcome Measure: Risk of fracture in current users vs nonusers of statins. Odds ratios were estimated from conditional logistic regression and adjusted for smoking, medications and illnesses associated with fracture risk, and body mass index when known.
Results: The adjusted odds ratio (OR) for current use of statins compared with nonuse was 1.01 (95% confidence interval [CI], 0.88-1.16). For forearm, hip, and vertebral fractures, the ORs were 1.01 (95% CI, 0.80-1.27), 0.59 (95% CI, 0.31-1.13), and 1.15 (95% CI, 0.62-2.14), respectively. Relative to nonuse, a statin dosage of less than 20 mg/d (standardized to simvastatin) was associated with an adjusted OR of fracture of 1.13 (95% CI, 0.96-1.33); this OR was 1.07 (95% CI, 0.82-1.38) at dosages of 20 to 39.9 mg/d and 0.85 (95% CI, 0.47-1.53) at dosages of 40 mg/d or more. The adjusted OR was 0.71 (95% CI, 0.50-1.01) for statin use durations of 0 to 3 months, 1.31 (95% CI, 0.87-1.95) for durations of 3 to 6 months, 1.14 (95% CI, 0.82-1.58) for durations of 6 to 12 months, and 1.17 (95% CI, 0.99-1.40) for durations of more than 12 months.
Conclusion: In this study, use of statins at dosages prescribed in clinical practice was not associated with a reduction in risk of fracture.

PDF 26060.pdf - Version of Record
Restricted to Repository staff only
Download (1MB)

More information

Published date: 11 April 2001
Organisations: Dev Origins of Health & Disease

Identifiers

Local EPrints ID: 26060
URI: http://eprints.soton.ac.uk/id/eprint/26060
ISSN: 0098-7484
PURE UUID: 50a5acc3-5bce-4f3d-9d96-a2586b722e32
ORCID for Cyrus Cooper: ORCID iD orcid.org/0000-0003-3510-0709

Catalogue record

Date deposited: 24 Apr 2006
Last modified: 17 Jul 2017 16:08

Export record

Altmetrics

Contributors

Author: Tjeerd-Pieter van Staa
Author: Sebastiaan Wegman
Author: Frank de Vries
Author: Bert Leufkens
Author: Cyrus Cooper ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×